Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line

References

• Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007;17:393–9
   PubMed Web of Science ®Google Scholar
• Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185–93
   PubMedGoogle Scholar
• Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193–201
   PubMed Web of Science ®Google Scholar
• Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncol (Williston Park) 1995;9:1149–58
   PubMedGoogle Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851–7
   PubMed Web of Science ®Google Scholar
• Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117–27
   PubMed Web of Science ®Google Scholar
• Koon HB, Atkins MB. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther 2007;7:79–88
   PubMed Web of Science ®Google Scholar
• Smith RA, Dumas J, Adnane L, Wilhelm SM. Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem 2006;6:1071–89
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2011/ucm268241.htm
   Google Scholar
• Nam BS, Kim H, Oh C-H, et al. Aminoquinoline derivatives with antiproliferative activity against melanoma cell line. Bioorg Med Chem Lett 2009;19:3517–20
   PubMed Web of Science ®Google Scholar
• Jung M-H, Kim H, Choi W-K, et al. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line. Bioorg Med Chem Lett 2009;19:6538–43
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jung M-H, Kim H, et al. Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. Bioorg Med Chem Lett 2010;20:413–17
   PubMed Web of Science ®Google Scholar
• Lee J, Kim H, Yu H, et al. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. Bioorg Med Chem Lett 201;20:1573–7
   PubMed Web of Science ®Google Scholar
• Yu H, Jung Y, Kim H, et al. 1, 4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors. Bioorg Med Chem Lett 2010;20:3805–8
   PubMed Web of Science ®Google Scholar
• Lee J, Nam BS, Kim H, et al. Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line. Bioorg Med Chem Lett 2010;20:5722–5
   PubMed Web of Science ®Google Scholar
• El-Gamal MI, Jung M-H, Lee WS, et al. Design, synthesis and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Eur J Med Chem 2011;46:3218–26
   PubMed Web of Science ®Google Scholar
• Choi W-K, El-Gamal MI, Choi HS, et al. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. Eur J Med Chem 2011;46:5754–62
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cho HJ, Kim H, et al. New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line. Bioorg Med Chem Lett 2012;22:3269–73
   PubMed Web of Science ®Google Scholar
• Jung MH, El-Gamal MI, Abdel-Maksoud MS, et al. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2. Bioorg Med Chem Lett 2012;22:4362–7
   PubMed Web of Science ®Google Scholar
• Cho HJ, El-Gamal MI, Oh C-H, et al. Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: design, synthesis, and antiproliferative activity against melanoma cell line. Chem Pharm Bull 2013;61:747–56
   PubMed Web of Science ®Google Scholar
• Koh EJ, El-Gamel MI, Oh C-H, et al. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies. Eur J Med Chem 2013;70:10–21
   PubMed Web of Science ®Google Scholar
• Ninkovic S, Braganza JF, Collins MR, et al. 6-Substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors. WO2010-016005 A1
   Google Scholar
• Orfi L, Wáczek F, Pató J, et al. Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. Curr Med Chem 2004;11:2549–53
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581–6
   PubMed Web of Science ®Google Scholar
• Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751–9
   PubMed Web of Science ®Google Scholar